P
ProHub
English 简体中文 繁體中文
Medium Growth Strategy Merger & Acquisition Inorganic Growth

Blockbuster Biosimilars

#Healthcare
ProHub Comment

This case combines market sizing with M&A decision-making, requiring candidates to identify revenue gaps from organic pipeline assets and then evaluate acquisition targets based on both financial metrics (ROI) and strategic fit. The case tests both quantitative analysis and qualitative business judgment, emphasizing that raw numbers alone don't determine the best choice when strategic alignment is a factor.

Estimated Time 26 minutes
Difficulty Medium
Source Duke
10 / 100
Your client is a multinational pharmaceutical and biologics company that specializes in innovative therapies across different disease types. The company is forecasting that biosimilars, a drug compound that is designed to have active properties similar to those of a drug that has already been licensed, will be released by a competitor within the next 12 months that will be marketed as replacements to your top grossing blockbuster drugs causing a significant loss of revenue. Your client has a long history of revenue growth, and has hired you to see how it can continue to grow.

Clarifying Information

  1. $50B a year in Revenue. Global Organization. Revenue Loss is Forecasted at 5% ($2.5B a year, so that is the number we are looking for).
  2. Lots of Smaller/Newer Biotech companies with promising drug pipelines. The industry is shifting from blockbuster drugs generating majority of revenue to more personalized and targeted drugs with higher impact, but smaller patient population.
  3. Currently commercialize 40 drugs with a very strong pipeline. The company has products in all major disease types, but is known for its oncology drugs, and believes that oncology will continue to be the future of the company.
  4. We do have promising late stage pipeline that we will give more information later on in case.
  5. Already in all major global markets. Large and robust manufacturing facilities regionally located in the United States.
  6. Want the $2.5B in revenue ASAP.
  7. Would like at least a 50% ROI on any acquired assets.
  8. Costs are not an issue, and should not be explored.
Mock Interview
Interviewer

Your client is a multinational pharmaceutical and biologics company that specializes in innovative therapies across different disease types. The company is forecasting that biosimilars, a drug compound that is designed to have active properties similar to those of a drug that has already been licensed, will be released by a competitor within the next 12 months that will be marketed as replacements to your top grossing blockbuster drugs causing a significant loss of revenue. Your client has a long history of revenue growth, and has hired you to see how it can continue to grow.

You

Thanks. Before analyzing, I'd like to clarify a few key questions...

Interviewer

Good question. Let me provide some background information...

You

Based on this, I suggest analyzing from these dimensions...

AI Score
Structure Analysis Communication Business Sense Quantitative
Practicing...
Score coming soon
Practice this case with AI Mock Interview

A pharmaceutical company facing a $2.5B revenue loss from biosimilar competition must identify growth opportunities. Candidates first quantify revenue potential from two near-commercialization drug assets, then evaluate three acquisition targets to fill a remaining $500M revenue gap, ultimately selecting Oncology Company A based on 50% immediate ROI and alignment with the client’s oncology expertise.

Key Insights:

  1. Market sizing requires multiple variables: patient population, market penetration, cost per treatment, dosage frequency, reimbursement rates, and probability of market success
  2. Organic growth from existing pipeline ($2B) is insufficient; inorganic growth through acquisition is necessary to meet the $2.5B target
  3. Strategic fit and competitive advantage (oncology expertise) can be as important as financial metrics when evaluating acquisition targets
  4. The 50% ROI constraint eliminates options and provides clear decision criteria for evaluating candidates